Q-omics provides the consensus-scored CST9L profile across patient tissues and cancer cell-line models. CST9L expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CST9L is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, CST9L protein abundance shows 13,500 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BRCA, and LUAD as cancer lineages where CST9L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CST9L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CST9L survival associations across molecular data types. CST9L RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CST9L RNA expression–survival associations across cancer types. High CST9L expression shows unfavorable associations in DLBC, KIRC, READ, COAD and TGCT, but favorable associations in BRCA. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CST9L RNA expression.
This table summarizes CST9L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4, while mass-spec protein shows differences in 3. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CST9L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CST9L shows higher tumor expression in BRCA, BLCA, UCEC and LUSC. The BRCA box plot shows higher CST9L RNA expression in tumor versus normal tissue (log2 FC = +0.272, t-test p = .002).
This table shows molecular features associated with CST9L in patient tissues and cancer cell lines. In patient samples, CST9L shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CST9L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
